Pam Ganju

Pam Ganju has an extensive work history in the pharmaceutical industry. Pam started their career at Novartis in 1997, where they worked as a Preclinical Neuropharmacology Research Group Leader, specializing in chronic pain treatment. During their time at Novartis, they led a successful international research program, resulting in numerous patents and scientific publications. Pam then joined Bristol-Myers Squibb in 2004, where they quickly advanced from a Medical Science Liaison to a Senior Medical Affairs Advisor. In this role, they played a key role in securing formulary applications, supporting clinical trials, and providing medical support to the UK Brand Team. In 2008, Pam joined Eisai as an Executive Director, Global Brand Lead for Halaven, an oncology drug. Pam continued to climb the ranks at Eisai, taking on various leadership positions, including Vice President of EMEA marketing & Business Unit Director Oncology. Currently, Pam holds the position of Vice President, Oncology Alliance Management, EMEA and Business Unit Director, UK & IRE at Eisai EMEA.

Pam Ganju obtained their Doctor of Philosophy (PhD) degree in Bacterial Molecular Genetics from Imperial College London. Additionally, they are a member of the General Pharmaceutical Council, as certified in 2014.